RESUMEN
Gabapentin, a selective ligand for the α2δ subunit of voltage-dependent calcium channels, is an anticonvulsant medication used in the treatment of neuropathic pain, epilepsy, and other neurological conditions. We recently described two radiofluorinated derivatives of gabapentin (trans-4-[18F]fluorogabapentin, [18F]tGBP4F, and cis-4-[18F]fluorogabapentin, [18F]cGBP4F) and showed that these compounds accumulate in the injured nerves in a rodent model of neuropathic pain. Given the use of gabapentin in brain diseases, here we investigate whether these radiofluorinated derivatives of gabapentin can be used for imaging α2δ receptors in the brain. Specifically, we developed automated radiosynthesis methods for [18F]tGBP4F and [18F]cGBP4F and conducted dynamic PET imaging in adult rhesus macaques with and without preadministration of pharmacological doses of gabapentin. Both radiotracers showed very high metabolic stability, negligible plasma protein binding, and slow accumulation in the brain. [18F]tGBP4F, the isomer with higher binding affinity, showed low brain uptake and could not be displaced, whereas [18F]cGBP4F showed moderate brain uptake and could be partially displaced. Kinetic modeling of brain regional time-activity curves using a metabolite-corrected arterial input function shows that a one-tissue compartment model accurately fits the data. Graphical analysis using Logan or multilinear analysis 1 produced similar results as compartmental modeling, indicating robust quantification. This study advances our understanding of how gabapentinoids work and provides an important advancement toward imaging α2δ receptors in the brain.
Asunto(s)
Neuralgia , Tomografía de Emisión de Positrones , Animales , Gabapentina/farmacología , Gabapentina/metabolismo , Macaca mulatta , Tomografía de Emisión de Positrones/métodos , Encéfalo/diagnóstico por imagen , Encéfalo/metabolismo , Neuralgia/metabolismoRESUMEN
BACKGROUND: Oral bioavailability (F), which is evaluated by permeability and solubility, is one of the key parameters in drug discovery. Currently, Caco-2 and Ussing chamber are both used in the study of intestinal permeability of drugs at different stages of drug development. However, comparative research between the Ussing chamber and Caco-2 for predicting the intestinal availability data (Fa×Fg) in humans has not been reported. METHODS: In the present study, we evaluated the permeability of 22 drugs in rat intestines by Ussing chamber and compared them with the reported permeability data from Caco-2. In addition, the active transport of gabapentin was evaluated by Ussing Chamber. RESULTS: Intestine segments were selected by corresponding absorption site for Ussing chamber analysis. BCS Class I and II compounds were more absorbed in the duodenum and jejunum, and Class III and IV compounds were more absorbed in the ileum. Papp values in the Caco-2 model were moderately correlated with human Fa×Fg (R2=0.722), and the Papp of the rat in the Ussing chamber revealed a better correlation with human Fa×Fg (R2=0.952). In addition, we also used the Ussing chamber to identify the transporter of gabapentin, and the results showed that the active absorption of gabapentin was related to LAT1. CONCLUSION: Ussing chamber combined with rat intestinal tissue would be a significant tool for predicting the intestinal absorption and metabolism of compounds with diverse physiochemical characteristics.
Asunto(s)
Absorción Intestinal , Yeyuno , Ratas , Humanos , Animales , Células CACO-2 , Gabapentina/metabolismo , Yeyuno/metabolismo , IntestinosRESUMEN
AIMS: Sepsis is a severe inflammatory response to infection with an incidence rate exceeding 48 million cases and 11 million sepsis-related deaths yearly. Furthermore, sepsis remains the fifth most common cause of death worldwide. The present study aimed to examine, for the first time, the potential hepatoprotective activity of gabapentin on cecal ligation and puncture (CLP)-induced sepsis in rats at the molecular level. MAIN METHODS: CLP was used as a model of sepsis in male Wistar rats. Histological examination and liver functions were evaluated. Levels of MDA, GSH, SOD, IL-6, IL-1ß, and TNF-α were investigated using ELISA. mRNA levels of Bax, Bcl-2, and NF-kB were assessed by qRT-PCR. Western blotting investigated the expression of ERK1/2, JNK1/2, and cleaved caspase 3 proteins. KEY FINDINGS: CLP resulted in liver damage, elevated serum levels of ALT, AST, ALP, MDA, TNF-α, IL-6, and IL-1ß, increased expression of ERK1/2, JNK1/2, and cleaved caspase 3 proteins, and upregulated Bax and NF-κB genes expression while it down-regulated Bcl-2 gene expression. However, gabapentin treatment significantly reduced the severity of CLP-induced biochemical, molecular, and histopathological changes. Gabapentin attenuated the levels of the proinflammatory mediators, decreased the expression of JNK1/2, ERK1/2, and cleaved caspase 3 proteins, suppressed Bax and NF-κB genes expression and increased the expression of the Bcl-2 gene. SIGNIFICANCE: Consequently, Gabapentin reduced hepatic injury resulting from CLP-induced sepsis by reducing proinflammatory mediators, attenuating apoptosis, and inhibiting the intracellular MAPK (ERK1/2, JNK1/2)-NF-kB signaling pathway.
Asunto(s)
FN-kappa B , Sepsis , Ratas , Masculino , Animales , FN-kappa B/metabolismo , Caspasa 3/metabolismo , Gabapentina/metabolismo , Factor de Necrosis Tumoral alfa/metabolismo , Sistema de Señalización de MAP Quinasas , Interleucina-6/metabolismo , Proteína X Asociada a bcl-2/metabolismo , Ratas Wistar , Transducción de Señal , Estrés Oxidativo , Punciones , Sepsis/complicaciones , Sepsis/tratamiento farmacológico , Sepsis/genética , ApoptosisRESUMEN
BACKGROUND: Neuropathic pain is a subtype of chronic pain characterized by a primary lesion or dysfunction of the peripheral or central nervous system. The current pain management of neuropathic pain is inadequate and needs new medications. AIM: We studied the effects of 14 days of intraperitoneal ellagic acid (EA) and gabapentin administration in a rat model of neuropathic pain induced by chronic constriction injury (CCI) of the right sciatic nerve. METHODS: Rats were divided into six groups: (1) control, (2) CCI, (3) CCI + EA (50 mg/kg), 4) CCI + EA (100 mg/kg), 5) CCI + gabapentin (100 mg/kg), and 6) CCI + EA (100 mg/kg) + gabapentin (100 mg/kg). Behavioral tests, including mechanical allodynia, cold allodynia, and thermal hyperalgesia, were conducted on days - 1(pre-operation), 7, and 14 post-CCI. In addition, at day 14 post-CCI, spinal cord segments were collected to measure the expression of inflammatory markers, including tumor necrosis factor-alpha (TNF-α), nitric oxide (NO), and oxidative stress markers, including malondialdehyde (MDA) and thiol. RESULTS: CCI increased mechanical allodynia, cold allodynia, and thermal hyperalgesia in rats which were reduced by treatment with EA (50 or 100 mg/kg), gabapentin, or their combination. CCI increased TNF-α, NO, and MDA levels and decreased thiol content in the spinal cord, which all were reverted by administration of EA (50 or 100 mg/kg), gabapentin, or their combination. CONCLUSION: This is the first report on ellagic acid's ameliorative effect in rats' CCI-induced neuropathic pain. This effect can be attributed to its anti-oxidative and anti-inflammatory, thus making it potentially useful as an adjuvant to conventional treatment.
Asunto(s)
Hiperalgesia , Neuralgia , Ratas , Animales , Gabapentina/farmacología , Gabapentina/metabolismo , Gabapentina/uso terapéutico , Hiperalgesia/tratamiento farmacológico , Hiperalgesia/metabolismo , Ácido Elágico/farmacología , Ácido Elágico/uso terapéutico , Ratas Sprague-Dawley , Factor de Necrosis Tumoral alfa/metabolismo , Neuralgia/tratamiento farmacológico , Neuralgia/metabolismo , Médula EspinalRESUMEN
In this hybrid review, we have first collected and reviewed available information on the structure and function of the enigmatic cache domains in α2δ proteins. These are organized into two double cache (dCache_1) domains, and they are present in all α2δ proteins. We have also included new data on the key function of these domains with respect to amino acid and gabapentinoid binding to the universal amino acid-binding pocket, which is present in α2δ-1 and α2δ-2. We have now identified the reason why α2δ-3 and α2δ-4 do not bind gabapentinoid drugs or amino acids with bulky side chains. In relation to this, we have determined that the bulky amino acids Tryptophan and Phenylalanine prevent gabapentin from inhibiting cell surface trafficking of α2δ-1. Together, these novel data shed further light on the importance of the cache domains in α2δ proteins.
Asunto(s)
Aminas , Canales de Calcio , Canales de Calcio/metabolismo , Gabapentina/metabolismo , Aminas/metabolismo , Aminas/farmacología , Membrana Celular/metabolismoRESUMEN
α2δ proteins serve as auxiliary subunits of voltage-gated calcium channels, which are essential components of excitable cells such as skeletal and heart muscles, nerve cells of the brain and the peripheral nervous system, as well as endocrine cells. Over the recent years, α2δ proteins have been identified as critical regulators of synaptic functions, including the formation and differentiation of synapses. These functions require signalling mechanisms which are partly independent of calcium channels. Hence, in light of these features it is not surprising that the genes encoding for the four α2δ isoforms have recently been linked to neurological and neurodevelopmental disorders including epilepsy, autism spectrum disorders, schizophrenia, and depressive and bipolar disorders. Despite the increasing number of identified disease-associated mutations, the underlying pathophysiological mechanisms are only beginning to emerge. However, a thorough understanding of the pathophysiological role of α2δ proteins ideally serves two purposes: first, it will contribute to our understanding of general pathological mechanisms in synaptic disorders. Second, it may support the future development of novel and specific treatments for brain disorders. In this context, it is noteworthy that the antiepileptic and anti-allodynic drugs gabapentin and pregabalin both act via binding to α2δ proteins and are among the top sold drugs for treating neuropathic pain. In this book chapter, we will discuss recent developments in our understanding of the functions of α2δ proteins, both as calcium channel subunits and as independent regulatory entities. Furthermore, we present and summarize recently identified and likely pathogenic mutations in the genes encoding α2δ proteins and discuss potential underlying pathophysiological consequences at the molecular and structural level.
Asunto(s)
Canales de Calcio , Epilepsia , Humanos , Canales de Calcio/metabolismo , Gabapentina/metabolismo , Sinapsis , Neuronas/metabolismo , Calcio/metabolismo , Subunidades de Proteína/genéticaRESUMEN
Autochthonous carbon fixation by algae and subsequent deposition of particulate organic matter can have significant effects on redox conditions and elimination of trace organic chemicals (TOrCs) in managed aquifer recharge (MAR). This study investigated the impacts of different algae loadings (0-160 g/m2) and infiltration rates (0.06-0.37 m/d) on overall oxygen consumption and elimination of selected TOrCs (diclofenac, formylaminoantipyrine, gabapentin, and sulfamethoxazole) in adapted laboratory sand columns. An infiltration rate of 0.37 m/d in conjunction with an algae load of 80 g/m2 (dry weight) sustained oxic conditions in the sand bed and did not affect the degradation of TOrCs. Thus, the availability of easily degradable organic carbon from algae did not influence the removal of TOrCs at an influent concentration of 1 µg/L. In contrast, a lower infiltration rate of 0.20 m/d in combination with a higher algae loading of 160 g/m2 caused anoxic conditions for 30 days and significantly impeded the degradation of formylaminoantipyrine, gabapentin, sulfamethoxazole, and diclofenac. Especially the elimination of gabapentin did not fully recover within 130 days after pulsed algae deposition. Hence, measures like micro-sieving or nutrient control are required at bank filtration or soil aquifer treatment sites with low infiltration rates.
Asunto(s)
Agua Subterránea , Contaminantes Químicos del Agua , Contaminantes Químicos del Agua/análisis , Arena , Diclofenaco , Gabapentina/metabolismo , Biodegradación Ambiental , Compuestos Orgánicos/metabolismo , Oxidación-ReducciónRESUMEN
Previous studies have indicated that the expression levels of several transporters are altered during placental trophoblast differentiation. However, changes in the transport activities of therapeutic agents during differentiation must be comprehensively characterised. Antiepileptic drugs, including gabapentin (GBP), lamotrigine (LTG), topiramate, and levetiracetam, are increasingly prescribed during pregnancy. The objective of this study was to elucidate differences in the uptake of antiepileptic drugs during the differentiation process.Human placental choriocarcinoma BeWo cells were used as trophoblast models. For differentiation into syncytiotrophoblast-like cells, cells were treated with forskolin.The uptake of GBP and LTG was lower in differentiated BeWo cells than in undifferentiated cells. In particular, the maximum uptake rate of GBP transport was decreased in differentiated BeWo cells. Furthermore, GBP transport was trans-stimulated by the amino acids His and Met. We investigated the profiles of amino acids in undifferentiated and differentiated BeWo cells. Supplementation with His and Met, which demonstrated trans-stimulatory effects on GBP uptake, restored GBP uptake in differentiated cells. The findings of this study suggest that drug transport in BeWo cells can be altered before and after differentiation, and that the altered GBP uptake could be mediated by the intracellular amino acid status.
Asunto(s)
Anticonvulsivantes , Placenta , Aminas/metabolismo , Aminoácidos/metabolismo , Anticonvulsivantes/metabolismo , Anticonvulsivantes/farmacología , Colforsina/metabolismo , Colforsina/farmacología , Femenino , Gabapentina/metabolismo , Gabapentina/farmacología , Humanos , Placenta/metabolismo , Embarazo , Trofoblastos/metabolismoRESUMEN
The present study aimed to design and optimize, a nanoconjugate of gabapentin (GPN)-melittin (MLT) and to evaluate its healing activity in rat diabetic wounds. To explore the wound healing potency of GPN-MLT nanoconjugate, an in vivo study was carried out. Diabetic rats were subjected to excision wounds and received daily topical treatment with conventional formulations of GPN, MLT, GPN-MLT nanoconjugate and a marketed formula. The outcome of the in vivo study showed an expedited wound contraction in GPN-MLT-treated animals. This was confirmed histologically. The nanoconjugate formula exhibited antioxidant activities as evidenced by preventing malondialdehyde (MDA) accumulation and superoxide dismutase (SOD) and glutathione peroxidase (GPx) enzymatic exhaustion. Further, the nanoconjugate showed superior anti-inflammatory activity as it inhibited the expression of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α). This is in addition to enhancement of proliferation as indicated by increased expression of transforming growth factor-ß (TGF- ß), vascular endothelial growth factor-A (VEGF-A) and platelet-derived growth factor receptor-ß (PDGFRB). Also, nanoconjugate enhanced hydroxyproline concentration and mRNA expression of collagen type 1 alpha 1 (Col 1A1). In conclusion, a GPN-MLT nanoconjugate was optimized with respect to particle size. Analysis of pharmacokinetic attributes showed the mean particle size of optimized nanoconjugate as 156.9 nm. The nanoconjugate exhibited potent wound healing activities in diabetic rats. This, at least partly, involve enhanced antioxidant, anti-inflammatory, proliferative and pro-collagen activities. This may help to develop novel formulae that could accelerate wound healing in diabetes.
Asunto(s)
Diabetes Mellitus Experimental , Factor A de Crecimiento Endotelial Vascular , Animales , Antiinflamatorios/uso terapéutico , Antioxidantes/metabolismo , Colágeno/metabolismo , Diabetes Mellitus Experimental/metabolismo , Gabapentina/metabolismo , Gabapentina/uso terapéutico , Meliteno/metabolismo , Meliteno/uso terapéutico , Nanoconjugados/uso terapéutico , Ratas , Ratas Wistar , Piel/metabolismo , Factor A de Crecimiento Endotelial Vascular/metabolismo , Cicatrización de HeridasRESUMEN
Since the retina continuously receives light to enable vision, reactive oxygen species (ROS) are easily generated in neural retina. The oxidative stress induced by ROS may be involved in the onset and progression of blinding aging diseases such as age-related macular degeneration, diabetic retinopathy, and glaucoma. Although supply of antioxidants to the retina is important to maintain the redox homeostasis in neural retina, the blood-retinal barrier (BRB) is created by complex tight-junctions of retinal capillary endothelial cells and retinal pigment epithelial cells to prevent the free diffusion of substances. The BRB is equipped with several membrane transporters to supply nutrients and essential molecules including antioxidants and drugs which exhibit antiaging effect to the retina from the circulating blood. In this review, the transporter-mediated retinal distribution of key endogenous compounds and drugs, such as vitamin C, l-cystine and gabapentin, is introduced for antiaging of the retina.
Asunto(s)
Antioxidantes/metabolismo , Ácido Ascórbico/metabolismo , Barrera Hematorretinal/metabolismo , Barrera Hematorretinal/fisiología , Especies Reactivas de Oxígeno/metabolismo , Retina/metabolismo , Animales , Cistina/metabolismo , Retinopatía Diabética/etiología , Retinopatía Diabética/prevención & control , Células Endoteliales/metabolismo , Gabapentina/metabolismo , Glaucoma/etiología , Glaucoma/prevención & control , Homeostasis , Humanos , Degeneración Macular/etiología , Degeneración Macular/prevención & control , Oxidación-Reducción , Estrés Oxidativo/fisiología , Ratas , Uniones Estrechas/metabolismoRESUMEN
The unbound concentrations of 14 commercial drugs, including five non-efflux/uptake transporter substrates-Class I, five efflux transporter substrates-class II and four influx transporter substrates-Class III, were simultaneously measured in rat liver, muscle, and blood via microanalysis. Kpuu,liver and Kpuu,muscle were calculated to evaluate the membrane transport activity and cell metabolism on the unbound drug concentrations in the skeletal muscle and liver. For Class I compounds, represented by antipyrine, unbound concentrations among liver, muscle and blood are symmetrically distributed when compound hepatic clearance is low. And when compound hepatic clearance is high, unbound concentrations among liver, muscle and blood are asymmetrically distributed, such as Propranolol. For Class II and III compounds, overall, the unbound concentrations among liver, muscle, and blood are asymmetrically distributed due to a combination of hepatic metabolism and efflux and/or influx transporter activity.
Asunto(s)
Membrana Celular/metabolismo , Hígado/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Músculo Esquelético/metabolismo , Preparaciones Farmacéuticas/metabolismo , Animales , Antipirina/sangre , Antipirina/metabolismo , Atenolol/sangre , Atenolol/metabolismo , Carbamazepina/sangre , Carbamazepina/metabolismo , Digoxina/sangre , Digoxina/metabolismo , Diltiazem/sangre , Diltiazem/metabolismo , Difenhidramina/sangre , Difenhidramina/metabolismo , Vías de Eliminación de Fármacos , Gabapentina/sangre , Gabapentina/metabolismo , Lamotrigina/sangre , Lamotrigina/metabolismo , Memantina/sangre , Memantina/metabolismo , Microdiálisis , Ofloxacino/sangre , Ofloxacino/metabolismo , Preparaciones Farmacéuticas/sangre , Propranolol/sangre , Propranolol/metabolismo , Pirilamina/sangre , Pirilamina/metabolismo , Quinidina/sangre , Quinidina/metabolismo , Ratas , Terfenadina/análogos & derivados , Terfenadina/sangre , Terfenadina/metabolismoRESUMEN
N-type voltage-gated calcium channels (CaV2.2) are predominantly expressed at presynaptic terminals, and their function is regulated by auxiliary α2δ and ß subunits. All four mammalian α2δ subunits enhance calcium currents through CaV1 and CaV2 channels, and this increase is attributed, in part, to increased CaV expression at the plasma membrane. In the present study we provide evidence that α2δ-1, like α2δ-2, is recycled to the plasma membrane through a Rab11a-dependent endosomal recycling pathway. Using a dominant-negative Rab11a mutant, Rab11a(S25N), we show that α2δ-1 increases plasma membrane CaV2.2 expression by increasing the rate and extent of net forward CaV2.2 trafficking in a Rab11a-dependent manner. Dominant-negative Rab11a also reduces the ability of α2δ-1 to increase CaV2.2 expression on the cell-surface of hippocampal neurites. In contrast, α2δ-3 does not enhance rapid forward CaV2.2 trafficking, regardless of whether Rab11a(S25N) is present. In addition, whole-cell CaV2.2 currents are reduced by co-expression of Rab11a(S25N) in the presence of α2δ-1, but not α2δ-3. Taken together these data suggest that α2δ subtypes participate in distinct trafficking pathways which in turn influence the localisation and function of CaV2.2.
Asunto(s)
Canales de Calcio Tipo L/metabolismo , Canales de Calcio/metabolismo , Proteínas de Unión al GTP rab/metabolismo , Animales , Encéfalo/metabolismo , Calcio/metabolismo , Canales de Calcio/genética , Canales de Calcio/fisiología , Canales de Calcio Tipo L/genética , Canales de Calcio Tipo N/genética , Canales de Calcio Tipo N/metabolismo , Línea Celular , Membrana Celular/metabolismo , Ácidos Ciclohexanocarboxílicos/metabolismo , Gabapentina/metabolismo , Hipocampo/metabolismo , Neuritas/metabolismo , Neuronas/metabolismo , Terminales Presinápticos/metabolismo , Cultivo Primario de Células , Transporte de Proteínas , Ratas , Ácido gamma-Aminobutírico/metabolismo , Proteínas de Unión al GTP rab/genéticaRESUMEN
AIMS: This study aimed to investigate the potential protective effects of vitamin E against gabapentin-induced chronic liver and kidney injury associated with the inhibition of biomarkers of apoptosis and tissue injury. MATERIALS AND METHODS: Four groups of adult male rats were included; control, gabapentin (100 mg/kg/day), Vitamin E (80 mg/kg/day), and a combination of gabapentin and Vitamin E for 90 days. Serum levels of AST, ALT, LDH, ALP, urea, and creatinine were measured in addition to malondialdehyde (MDA), and reduced glutathione (GSH) tissue levels. P53 gene expression, histological, and immunohistochemical examinations were performed in liver and kidney tissue samples. KEY FINDINGS: Gabapentin increased AST, ALT, LDH, ALP, urea, creatinine, MDA, and p53 gene expression and it reduced GSH. Moreover, gabapentin administration caused structural changes in the hepatic and renal architecture with a weak Periodic acid-Schiff (PAS) reaction that reflects glycogen deposition in the liver and kidney and a positive immunoreaction for BCL2-associated X protein (BAX) that reflects activated apoptosis. Vitamin E significantly (p<0.05) reversed the biochemical alterations associated with chronic gabapentin administration and improved the histopathological picture of hepatic and renal tissue with a partial inhibition of BAX. SIGNIFICANCE: Chronic administration of gabapentin causes hepatic and renal impairments, which is ameliorated by Vitamin E; possibly due to the inhibition of biomarkers of apoptosis and tissue injury.
Asunto(s)
Gabapentina/efectos adversos , Vitamina E/farmacología , Animales , Antioxidantes/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/fisiología , Biomarcadores/metabolismo , Creatinina/metabolismo , Gabapentina/metabolismo , Gabapentina/toxicidad , Glutatión/metabolismo , Riñón/efectos de los fármacos , Riñón/metabolismo , Riñón/patología , Enfermedades Renales/patología , Hígado/efectos de los fármacos , Hígado/metabolismo , Hígado/patología , Masculino , Malondialdehído/metabolismo , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Sustancias Protectoras/farmacología , Ratas , Ratas Wistar , Vitamina E/metabolismoRESUMEN
Potential risks to the fetus or infant should be considered prior to medication during pregnancy and lactation. It is essential to evaluate the exposure levels of drugs and their related factors in addition to toxicological effects. Epilepsy is one of the most common neurological complications in pregnancy; some women continue to use antiepileptic drugs (AEDs) to control seizures. Benzodiazepines (BZDs) are widely prescribed for several women who experience symptoms such as anxiety and insomnia during the postpartum period. In this review, we describe the 1) transport mechanisms of AEDs across the placenta and the effects of these drugs on placental transporters, and 2) the transfer of BZDs into breast milk. Our findings indicated that carrier systems were involved in the uptake of gabapentin (GBP) and lamotrigine (LTG) in placental trophoblast cell lines. SLC7A5 was the main contributor to GBP transport in placental cells. LTG was transported by a carrier that was sensitive to chloroquine, imipramine, quinidine, and verapamil. Short-term exposure to 16 AEDs had no effect on folic acid uptake in placental cells. However, long-term exposure to valproic acid (VPA) affected the expression of folate carriers (FOLR1, SLC46A1). Furthermore, VPA administration changed the expression levels of various transporters in rat placenta, suggesting that sensitivity to VPA differed across gestational stages. Lastly, we developed a method for quantifying eight BZDs in human breast milk and plasma using LC/MS/MS, and successfully applied it to quantify alprazolam in breast milk and plasma donated by a lactating woman.
Asunto(s)
Anticonvulsivantes/metabolismo , Benzodiazepinas/metabolismo , Transporte Biológico/genética , Lactancia Materna , Gabapentina/metabolismo , Lactancia/metabolismo , Lamotrigina/metabolismo , Transportador de Aminoácidos Neutros Grandes 1/fisiología , Intercambio Materno-Fetal , Leche Humana/metabolismo , Placenta/metabolismo , Ácido Valproico/metabolismo , Anticonvulsivantes/efectos adversos , Benzodiazepinas/efectos adversos , Benzodiazepinas/uso terapéutico , Línea Celular , Epilepsia/tratamiento farmacológico , Femenino , Receptor 1 de Folato/genética , Receptor 1 de Folato/metabolismo , Gabapentina/efectos adversos , Expresión Génica/efectos de los fármacos , Humanos , Lamotrigina/efectos adversos , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Transportador de Folato Acoplado a Protón/genética , Transportador de Folato Acoplado a Protón/metabolismo , Ácido Valproico/efectos adversosRESUMEN
The aim of this study was to evaluate the prevalence and abuse potential of antiepileptic drugs (AEDs) among prison populations in Scotland, UK. Participants consisted of all admitted and released prisoners over a 1 month period who consented to provide samples. Urine samples were collected and analyzed by liquid chromatography coupled with triple quadrupole tandem mass spectrometry using a method validated for the simultaneous quantification of 21 AEDs in urine. A total of 904 samples were collected. The samples were also screened for drugs of abuse by using point-of-care testing kits. A total of 18% of the samples were positive for AEDs. Gabapentin (GBP) was identified in 118 samples (13%) and pregabalin (PRG) in 32 samples (3.5%). Interestingly, 12 samples contained both drugs (1.3%). The concentrations ranged from 0.5 to 1,100 mg/L (median, 15 mg/L) for GBP and from 0.5 to 440 mg/L (median, 7.3 mg/L) for PRG. Four samples were found to have concentrations >400 mg/L, two samples for GBP and two samples for PRG. These concentrations are at least 20 times above the median concentrations. Other AEDs detected were levetiracetam (four samples), vigabatrin (four samples), lamotrigine (three samples), valproic acid (three samples), carbamazepine (two samples) and topiramate (one sample). Illicit or non-prescribed drugs were detected in 81% of urine samples of which 80% were from admitted prisoners and 20% from released prisoners. Benzodiazepines, opiates and cannabis were the most frequently detected drugs. Other drugs found in positive AED samples were methadone (26%), cocaine (18%), buprenorphine (17%), amphetamines (4%), methamphetamines (4%) and barbiturates (4%). This study shows a high prevalence of AEDs within the Scottish prison system, primarily due to GBP and PRG; however, due to the anonymity of the sample collection, it is unknown if these are prescribed or illicit drug ingestions.
Asunto(s)
Gabapentina/metabolismo , Pregabalina/metabolismo , Prisioneros , Trastornos Relacionados con Sustancias/epidemiología , Femenino , Humanos , Masculino , Escocia/epidemiología , Detección de Abuso de SustanciasRESUMEN
BACKGROUND: Use of gabapentinoids is increasing. Following recent case reports, we investigated a putative risk of parkinsonism with pregabalin or gabapentin. METHODS: A disproportionality analysis of 5,653,547 individual case safety reports in the World Health Organization individual case safety report database, VigiBase, compared all patients with parkinsonism who were receiving gabapentinoids with other patients. Results are shown as reporting odds ratios and the information component, an indicator of disproportionate Bayesian reporting. Sensitivity analyses included comparisons with drugs used for similar indications (amitriptyline, duloxetine) and exclusion of drugs that induce parkinsonism. RESULTS: Among 5,653,547 reports, 4925 parkinsonism reports were found with pregabalin and 4881 with gabapentin. Gabapentin and pregabalin were associated with increased reporting odds ratio (2.16 [2.10-2.23], 2.43 [2.36-2.50]). Similar trends were found using information components after excluding drugs that induce parkinsonism and for pregabalin compared with amitriptyline or duloxetine. CONCLUSIONS: This study found that gabapentinoids (particularly pregabalin) can be associated with parkinsonism. © 2019 International Parkinson and Movement Disorder Society.
Asunto(s)
Gabapentina/metabolismo , Trastornos Parkinsonianos/metabolismo , Preparaciones Farmacéuticas/metabolismo , Pregabalina/metabolismo , Ácido gamma-Aminobutírico/metabolismo , Anciano , Teorema de Bayes , Femenino , Gabapentina/farmacología , Humanos , Masculino , Persona de Mediana Edad , Pregabalina/farmacologíaRESUMEN
An amphetamine interference was observed during the development of an liquid chromatography-high-resolution mass spectrometry (LC-HRMS) multi-class confirmation method for the determination of 47 drugs and metabolites in urine. The interference passed all qualitative criteria for amphetamine leading to potential false-positive results. Upon investigation, it was found that the amphetamine interference was correlated with the presence of high levels of gabapentin. Gabapentin is routinely detected in patient urine specimens at levels in excess of 1 mg/mL as it is widely prescribed at high doses and does not undergo significant metabolism. The source of the interference was identified as a gabapentin in-source fragment isomeric with protonated amphetamine. Here we describe the characterization of this interference and how its effect was mitigated in the LC-HRMS method.
Asunto(s)
Anfetamina/metabolismo , Gabapentina/metabolismo , Anfetamina/química , Cromatografía Líquida de Alta Presión , Cromatografía Liquida , Gabapentina/química , HumanosRESUMEN
The α2δ-1 subunit of voltage-gated calcium channels binds to gabapentin and pregabalin, mediating the analgesic action of these drugs against neuropathic pain. Extracellular matrix proteins from the thrombospondin (TSP) family have been identified as ligands of α2δ-1 in the CNS. This interaction was found to be crucial for excitatory synaptogenesis and neuronal sensitisation which in turn can be inhibited by gabapentin, suggesting a potential role in the pathogenesis of neuropathic pain. Here, we provide information on the biochemical properties of the direct TSP/α2δ-1 interaction using an ELISA-style ligand binding assay. Our data reveal that full-length pentameric TSP-4, but neither TSP-5/COMP of the pentamer-forming subgroup B nor TSP-2 of the trimer-forming subgroup A directly interact with a soluble variant of α2δ-1 (α2δ-1S). Interestingly, this interaction is not inhibited by gabapentin on a molecular level and is not detectable on the surface of HEK293-EBNA cells over-expressing α2δ-1 protein. These results provide biochemical evidence that supports a specific role of TSP-4 among the TSPs in mediating the binding to neuronal α2δ-1 and suggest that gabapentin does not directly target TSP/α2δ-1 interaction to alleviate neuropathic pain.
Asunto(s)
Canales de Calcio Tipo L/metabolismo , Gabapentina/metabolismo , Trombospondinas/metabolismo , Ensayo de Inmunoadsorción Enzimática , Células HEK293 , Humanos , Ligandos , Espectrometría de Masas , Proteínas de la Membrana/química , Proteínas de la Membrana/metabolismoRESUMEN
Introduction: Restless Legs Syndrome/Willis-Ekbom disease (RLS/WED) is a common sensory-motor neurological disorder that impairs nocturnal rest causing decreased alertness, depressed mood, reduced job performance and poor quality of life. In patients affected by moderate to severe RLS/WED, a pharmacological treatment is mandatory. Areas covered: The present review is based on an extensive Internet and PubMed search from 1996 to 2019. It is focused on drugs currently used and under development (phase III and beyond) for the treatment of RLS/WED. Expert opinion: The drugs currently available for the treatment of the disease do not always allow for obtaining the optimal control of symptoms, in particular in the long-term treatment. Although initially effective, long-term dopaminergic treatment tends to wane over time and augmentation can occur. Updated international guidelines now recommend α2δ calcium channel ligand medications as the initial drug of choice. Oxycodone-naloxone demonstrated a significant and sustained treatment effect for patients with severe RLS/WED insufficiently controlled with previous treatments. Head-to-head trials of different drugs, as well as more studies on nondopaminergic agents and combination therapy, are greatly needed. Monoamine oxidase B inhibitors could be good candidates for the initial treatment of RLS/WED, sparing stronger dopaminergic agents for later stages of the disease.
Asunto(s)
Agonistas de Dopamina/uso terapéutico , Síndrome de las Piernas Inquietas/tratamiento farmacológico , Canales de Calcio/química , Canales de Calcio/metabolismo , Agonistas de Dopamina/química , Agonistas de Dopamina/metabolismo , Gabapentina/química , Gabapentina/metabolismo , Gabapentina/uso terapéutico , Humanos , Pramipexol/química , Pramipexol/metabolismo , Pramipexol/uso terapéutico , Pregabalina/química , Pregabalina/metabolismo , Pregabalina/uso terapéutico , Síndrome de las Piernas Inquietas/patología , Tetrahidronaftalenos/química , Tetrahidronaftalenos/metabolismo , Tetrahidronaftalenos/uso terapéutico , Tiofenos/química , Tiofenos/metabolismo , Tiofenos/uso terapéutico , Topiramato/química , Topiramato/metabolismo , Topiramato/uso terapéuticoRESUMEN
Highly effective and safe drugs for the treatment of neuropathic pain are urgently required and it was shown that blocking T-type calcium channels can be a promising strategy for drug development for neuropathic pain. We have developed pyrrolidine-based T-type calcium channel inhibitors by structural hybridization and subsequent assessment of in vitro activities against Cav3.1 and Cav3.2 channels. Profiling of in vitro ADME properties of compounds was also carried out. The representative compound 17h showed comparable in vivo efficacy to gabapentin in the SNL model, which indicates T-type calcium channel inhibitors can be developed as effective therapeutics for neuropathic pain.